Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK.

AIDS. 2011 Jun 19;25(10):1281-8. doi: 10.1097/QAD.0b013e328347f3f1.

2.

Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.

Montague TH, Potvin D, Diliberti CE, Hauck WW, Parr AF, Schuirmann DJ.

Pharm Stat. 2012 Jan-Feb;11(1):8-13. doi: 10.1002/pst.483. Epub 2011 Feb 10.

PMID:
21308974
3.

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.

J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16.

PMID:
20554713
4.

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff.

PMID:
20101189
5.

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

AIDS. 2008 Sep 12;22(14):1719-28. doi: 10.1097/QAD.0b013e32830a5058.

PMID:
18690162
6.

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

N Engl J Med. 2007 Dec 6;357(23):2359-70.

7.

Sequential design approaches for bioequivalence studies with crossover designs.

Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA.

Pharm Stat. 2008 Oct-Dec;7(4):245-62.

PMID:
17710740
8.
9.

Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man.

Labbé L, Robitaille NM, Lefez C, Potvin D, Gilbert M, O'Hara G, Turgeon J.

Ther Drug Monit. 2004 Oct;26(5):492-8.

PMID:
15385831
10.

A qualitative study of attitudes toward error in patients facing brain tumour surgery.

Bernstein M, Potvin D, Martin DK.

Can J Neurol Sci. 2004 May;31(2):208-12.

PMID:
15198445
11.

Carry-over effects in bioequivalence studies.

Dangelo G, Potvin D, Turgeon J.

J Biopharm Stat. 2001 Feb-May;11(1-2):35-43.

PMID:
11459441
12.

Numerical methods for the evaluation of individual bioequivalence criteria.

Kimanani EK, Lavigne J, Potvin D.

Stat Med. 2000 Oct 30;19(20):2775-95.

PMID:
11033575
13.

Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability.

Lalonde RL, Ouellet D, Kimanani EK, Potvin D, Vaughan LM, Hill MR.

J Pharmacokinet Biopharm. 1999 Feb;27(1):67-83.

PMID:
10533698
14.

Enabling factors related to prosthetic use by people with transtibial and transfemoral amputation.

Gauthier-Gagnon C, Grisé MC, Potvin D.

Arch Phys Med Rehabil. 1999 Jun;80(6):706-13.

PMID:
10378500
15.
16.

A parametric confidence interval for a moment-based scaled criterion for individual bioequivalence.

Kimanani EK, Potvin D.

J Pharmacokinet Biopharm. 1997 Oct;25(5):595-614.

PMID:
9679224
17.

Multistage designs for phase II clinical trials: statistical issues in cancer research.

Kramar A, Potvin D, Hill C.

Br J Cancer. 1996 Oct;74(8):1317-20. Review.

18.

[Research design for patient selection in clinical trials phase II].

Kramar A, Potvin D, Hill C.

Rev Epidemiol Sante Publique. 1996 Aug;44(4):364-71. French.

PMID:
8927779
19.

Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.

Lambert M, Lupien PJ, Gagné C, Lévy E, Blaichman S, Langlois S, Hayden M, Rose V, Clarke JT, Wolfe BM, Clarson C, Parsons H, Stephure DK, Potvin D, Lambert J.

Pediatrics. 1996 May;97(5):619-28.

PMID:
8628597
20.

Factors associated with length of survival among 1081 terminally ill cancer patients.

Allard P, Dionne A, Potvin D.

J Palliat Care. 1995 Autumn;11(3):20-4.

PMID:
7472787
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk